Palomino Laboratories reported cash from operations of -$0.31M and free cash flow of -$0.31M for the quarter ended Sep 2025. This cash flow statement covers 9 quarters of results from Sep 2023 through Sep 2025, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Net Income | -0.04M | -0.03M | -0.05M | -0.03M | -0.00M | -0.14M | -0.03M | -0.35M | -1.61M |
| Share-based CompensationStock Comp. | 2.44M | 0.01M | 0.15M | 1.26M | |||||
| Cash from OperationsCash from Ops. | -0.06M | 0.03M | -0.17M | 0.00M | -0.08M | -0.31M | |||
| Change in Working Capital | |||||||||
| Change in Account PayablesChange Payables | 0.00M | 0.00M | 0.00M | 0.00M | -0.01M | -0.03M | 0.01M | 0.12M | -0.07M |
| Change in Accured ExpensesChange Accured Exp. | -0.03M | 0.05M | -0.00M | 0.00M | -0.04M | 0.04M | -0.01M | 0.46M | |
| Financing Activities | |||||||||
| Cash from Financing ActivitiesCash from Financing | 0.06M | 0.02M | 0.14M | 20.00 | 1.67M | 6.48M | |||
| Change in Capital Stock | |||||||||
| Net Equity Issued and RepurchasedNet Equity Issued | 8.02M | ||||||||
| Additional items | |||||||||
| Change in Cash | 888.00 | 0.03M | 0.00M | 1.59M | 6.17M | ||||
| Free Cash FlowFCF | -0.06M | 0.03M | -0.17M | 0.00M | -0.08M | -0.31M | |||
| Net Cash FlowNCF | 0.05M | -0.02M | 0.00M | 1.59M | 6.17M |